The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): A randomised, placebo-controlled, double-blind trial

The Lancet

Volumn 377, Issue 9767, 2011, Pages 741-750

  Sandset, Else Charlotte ^a,b   Bath, Philip M W ^c   Boysen, Gudrun ^d   Jatuzis, Dalius ^e   Kõrv, Janika ^f   Lüders, Stephan ^g   Murray, Gordon D ^h   Richter, Przemyslaw S ⁱ   Roine, Risto O ^j   Terént, Andreas ^k   Thijs, Vincent ^l   Berge, Eivind ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e VILNIUS UNIVERSITY   (Lithuania)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

^g ST JOSEFS HOSPITAL   (Germany)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^j TURKU UNIVERSITY HOSPITAL   (Finland)

^k UPPSALA UNIVERSITY   (Sweden)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; PLACEBO;

AGED; ARTICLE; BARTHEL INDEX; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EUROPE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 79952103780     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60104-9     Document Type: Article

References (39)

1. Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007; 25: 32-38. (Pubitemid 44869006)
2. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33: 1315-20. (Pubitemid 34517053)
3. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004; 43: 18-24. (Pubitemid 38031905)
4. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008; 118: 176-87.
5. Geeganage C, Bath PM. Vasoactive drugs for acute stroke. Cochrane Database Syst Rev 2010; 7: CD002839.
6. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478-534.
7. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
8. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/ American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation 2007; 116: e391-413.
9. Strandgaard S. Autoregulation of cerebral circulation in hypertension. Acta Neurol Scand 1978; 57 (suppl 66): 1-82. (Pubitemid 8341500)
10. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of Nimodipine in the Treatment of Acute Ischaemic Stroke. Cerebrovasc Dis 1994; 4: 204-10.
11. Fagan SC, Kozak A, Hill WD, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24: 535-39. (Pubitemid 43261918)
12. Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther 2008; 326: 773-82.
13. Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-703. (Pubitemid 36842630)
14. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
16. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86. (Pubitemid 36677151)
17. Sandset EC, Murray G, Boysen G, et al. Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). Int J Stroke 2010; 5: 423-27.
18. Lindenstrøm E, Boysen G, Christiansen LW, Hansen BR, Nielsen PW. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovasc Dis 1991; 1: 103-07.
19. Bonita R, Beaglehole R. Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988; 12: 1497-500. (Pubitemid 19005804)
20. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009; 107: 403-05.
21. Loewen SC, Anderson BA. Predictors of stroke outcome using objective measurement scales. Stroke 1990; 21: 78-81. (Pubitemid 20052534)
22. Berge E, Barer D. Could stroke trials be missing important treatment eff ects? Cerebrovasc Dis 2002; 13: 73-75. (Pubitemid 34124176)
23. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007; 38: 1911-15. (Pubitemid 46847268)
24. McHugh GS, Butcher I, Steyerberg EW, et al. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project. Clin Trials 2010; 7: 44-57.
25. Murray GD, Barer D, Choi S, et al. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005; 22: 511-17. (Pubitemid 40726979)
26. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-02.
27. Gray LJ, Ali M, Lyden PD, Bath PM. Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in acute stroke. J Stroke Cerebrovasc Dis 2009; 18: 466-68.
28. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JRA. Low dose beta blockade in acute stroke (BEST trial): an evaluation. BMJ 1988; 296: 737-41. (Pubitemid 18066502)
29. Azcona A, Lataste X. Isradipine in patients with acute ischaemic cerebral infarction. Drugs 1990; 40 (suppl 2): 52-57.
30. Norris JW, Le Brun LH, Anderson BA. Intravenous nimodipine in acute ischaemic stroke. Cerebrovasc Dis 1994; 4: 194-96.
31. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled rial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994; 25: 1348-53. (Pubitemid 24198578)
32. Limburg M, Horn J, Vermeulen M, for the VENUS Group. VENUS: Very Early Nimodipine Use in Stroke. Stroke 1995; 26: 353 (abstr).
33. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. The eff ects of lifarizine in acute cerebral infarction: a pilot safety study. Cerebrovasc Dis 1996; 6: 156-60.
34. Ahmed N, Nasman P, Wahlgren NG. Eff ects of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000; 31: 1250-55. (Pubitemid 30351241)
35. IMAGES investigators. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): randomised controlled trial. Lancet 2004; 363: 439-45.
36. Anderson CS, Huang Y, Wang JG, et al, for the INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7: 391-99.
37. Delcourt C, Huang Y, Wang J, et al. The second (main) phase of an open, randomised, multicentre study to investigate the eff ectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). Int J Stroke 2010; 5: 110-16.
38. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 2006; 1: 245-49.
39. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.